Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies

Clinical Pharmacology and Therapeutics

Volumn 103, Issue 2, 2018, Pages 318-331

  Komaki, Y ^a   Komaki, F ^a   Yamada, A ^a,b   Micic, D ^c   Ido, A ^d   Sakuraba, A ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^c NORTHWESTERN UNIVERSITY   (United States)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN;

ARTICLE; CLINICAL FEATURE; COLITIS; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; HUMAN; IMMUNE RELATED COLITIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RASH; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ADVERSE DRUG REACTION; AGED; ANTAGONISTS AND INHIBITORS; DATA MINING; EVIDENCE BASED MEDICINE; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM; PATHOLOGY; PATIENT SAFETY; PROCEDURES; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CTLA-4 ANTIGEN; DATA MINING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SAFETY; PROGRAMMED CELL DEATH 1 RECEPTOR; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 85040255649     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.633     Document Type: Article

References (50)

1. Sharma, P. & Allison, J.P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
2. Xia, B. & Herbst, R.S. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy 8, 279–298 (2016).
3. Gardiner, D. et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8, e63818 (2013).
4. Johnson, D.B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).
5. Shahabi, V. et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J. Transl. Med. 11, 75 (2013).
6. Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.E. & Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13, 211 (2015).
7. Minkis, K., Garden, B.C., Wu, S., Pulitzer, M.P. & Lacouture, M.E. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J. Am. Acad. Dermatol. 69, e121–128 (2013).
8. Abdel-Rahman, O., ElHalawani, H. & Fouad, M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 11, 2471–2484 (2015).
9. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
10. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
11. Lynch, T.J. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046–2054 (2012).
12. Reck, M. et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann. Oncol. 24, 75–83 (2013).
13. Kwon, E.D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).
14. Eggermont, A.M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
15. Reck, M. et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J. Clin. Oncol. (2016) [Epub ahead of print].
16. Ribas, A. et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31, 616–622 (2013).
17. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
18. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
19. Motzer, R.J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
20. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
21. Weber, J.S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
22. Ferris, R.L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
23. Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918 (2015).
24. Herbst, R.S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).
25. Langer, C.J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
26. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
27. Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837–1846 (2016).
28. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (2016) [Epub ahead of print].
29. Bour-Jordan, H. & Bluestone, J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41–66 (2009).
30. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
31. Weber, J.S., Dummer, R., de Pril, V., Lebbe, C., Hodi, F.S. & Investigators, M.D.X. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119, 1675–1682 (2013).
32. Verschuren, E.C. et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin. Gastroenterol. Hepatol. 14, 836–842 (2016).
33. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
34. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
35. Postow, M.A., Callahan, M.K. & Wolchok, J.D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974–1982 (2015).
36. Weber, J.S., Kahler, K.C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).
37. Belum, V.R. et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur. J. Cancer 60, 12–25 (2016).
38. Gutzmer, R., Wollenberg, A., Ugurel, S., Homey, B., Ganser, A. & Kapp, A. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch. Arztebl. Int. 109, 133–140 (2012).
39. Okiyama, N. & Fujimoto, M. Clinical perspectives and murine models of lichenoid tissue reaction/interface dermatitis. J. Dermatol. Sci. 78, 167–172 (2015).
40. Sedgwick, P. Meta-analyses: how to read a funnel plot. Br. Med. J. 346, f1342 (2013).
41. Higgins, J. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1. 0. London: The Cochrane Collaboration; (2011).
42. Grigg, C. & Rizvi, N.A. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J. Immunother. Cancer 4, 48 (2016).
43. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62, 1006–1012 (2009).
44. Jadad, A.R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1–12 (1996).
45. Nguyen, P.L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359–2366 (2011).
46. Huedo-Medina, T.B., Sanchez-Meca, J., Marin-Martinez, F. & Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods 11, 193–206 (2006).
47. Higgins, J.P., Thompson, S.G., Deeks, J.J. & Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 327, 557–660 (2003).
48. Pereira, T.V., Patsopoulos, N.A., Salanti, G. & Ioannidis, J.P. Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity. Res. Synth. Methods 1, 149–161 (2010).
49. Begg, C.B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101 (1994).
50. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634 (1997).